Kenda Alkwatli
Endocrinology, Diabetes & Metabolism · Wethersfield, CTNPI 1063075901
Payments from drug & device makers
Across 67 payments — averaging $31.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$418
- Amgen$361
- Novo Nordisk$241
- Abbott$188
- Chiesi USA, Inc.$130
- Xeris Pharmaceuticals, Inc.$126
- plus $676 from 15 others
What the payments were for
- Food & beverage$2,142100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 3 | $418 |
| Amgen | 7 | $361 |
| Novo Nordisk | 15 | $241 |
| Abbott | 5 | $188 |
| Chiesi USA, Inc. | 1 | $130 |
| Xeris Pharmaceuticals, Inc. | 6 | $126 |
| Lilly USA, LLC | 8 | $124 |
| Corcept Therapeutics | 4 | $103 |
| Mannkind Corporation | 1 | $68 |
| BETA Bionics, Inc. | 3 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| Amneal Pharmaceuticals LLC | 2 | $45 |
| AbbVie | 2 | $41 |
| AstraZeneca | 1 | $31 |
| Sequel Med Tech, LLC | 1 | $27 |
| GSK | 1 | $25 |
| Tandem Diabetes Care, Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $24 |
| Sandoz | 1 | $23 |
| 3b Medical, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$400
- EVENITY$228
- MYALEPT$130
- FREESTYLE LIBRE 3$110
How this compares
$2,142 in reported general payments places this provider in the 60th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 19 | $24,467 |
| Levothyroxine Sodium | 15 | $210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $241 | $24,46719 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $45 | $21015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Wethersfield
- Ania JastreboffNew Haven$2.2M
- Ilja HulinskyBridgeport$1.6M
- Gerald ShulmanNew Haven$1M
- Karl InsognaNew Haven$903K
- Clemens BergwitzNew Haven$735K
- Egils BogdanovicsTorrington$608K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Francis WilsonNew Haven$415K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.